Turning Point Therapeutics, a San Diego-based developer of targeted cancer drugs, is presenting updated data Friday showing that its targeted therapy helps lung cancer patients whose disease is driven by a rare genetic alteration.
The drug, repotrectinib, has been tested in 33 patients whose cancer is driven by an alteration of a gene called ROS1. Eleven of these patients have not previously been treated with another drug; of these, nine, or 82%, saw their tumors shrink by at least 30%. (Doctors call this shrinkage a “response.”)
About the Author Reprints
